drugset / Press release
Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Develop and Commercialize Phase 2-stage KRN23 for X-linked Hypophosphatemia
2013-09-03 · Ultragenyx Pharmaceutical Inc · original ultragenyx.com ↗
Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Develop and Commercialize Phase 2-stage KRN23 for X-linked Hypophosphatemia
The release as fetched from its publisher. ultragenyx.com ↗